✕

Download the Practo app for free

Get Rs. 200 HealthCash
Download the app now
✔ Book instant appointments 24x7
✔ Bookmark doctors for quick access
✔ Consult online with a doctor in 60s
✕
Free ₹200 worth HealthCash on app
Use HealthCash to order medicines, health products & much more
Get App
0

Reditux Ra 500 mg Infusion

Manufactured byDR REDDYS LABORATORIES LTD
ContainsRituximab
CURRENTLY UNAVAILABLE

Description

Reditux Ra 500 mg Infusion is an anticancer medicine that is used alone or in a combination with other medicines for the treatment of various types of blood cancers. It is also used for the treatment of autoimmune diseases such as rheumatoid arthritis, microscopic polyangitis, Wegener's granulomatosis etc.
QUICK LINKS:
Side effectsConcernsUsageRelated products

How will this medicine affect me?

Consult top doctors online and get an answer now.
Consult now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now

Should you be taking this medicine?

Consult with a Doctor for the best diagnosis.

Looking for a doctor?

Book an appointment with the top doctors near you

Substitutes

List of substitutes for Reditux Ra 500 mg Infusion

Ristova 500 mg Injection
Roche India
Cytomab 500 mg Injection
Alkem Laboratories Ltd.
Toritz 500 Injection
Torrent Pharmaceuticals Ltd.
LupiximAb 500 Injection
Lupin Ltd.

Side effects

Major & minor side effects for Reditux Ra 500 mg Infusion

Low blood pressure

Nausea and Vomiting

Chills and fever

Abdominal pain

Decrease in white blood cells and platelets

Itching

Infections

Headache

Muscle aches and pain

Cough

Uses of Reditux Ra 500 mg Infusion

What is it prescribed for?

Non-Hodgkin's Lymphoma

This medicine is used in the treatment of non-Hodgkin's lymphoma, a type of cancer that affects certain cells (lymphocytes) of the lymphatic system.

Chronic Lymphocytic Leukaemia

This medicine is used in the treatment of chronic lymphocytic leukemia, a type of blood cancer.

Rheumatoid Arthritis

This medicine is used in the treatment of Rheumatoid Arthritis, a chronic condition that can affect many joints.

Granulomatosis with polyangiitis and microscopic polyangiitis

This medicine is used in a combination with other medicines for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis, chronic conditions that affect the blood vessels and may cause damage to the organs.
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?

    The initial response to this medicine can be observed within 7 to 14 days of administration.

  • How long do the effects of this medicine last?

    The effect of this medicine can be detected for up to 6 months after completion of the treatment.

  • Is it safe to consume alcohol while taking this medicine?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is this a habit forming medicine?

    No habit-forming tendencies were reported.

  • Can this medicine be taken during pregnancy?

    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

  • Can this medicine be taken while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to rituximab, any murine proteins, or any other inactive ingredients present along with it.

Active infections

This medicine is not recommended for use in patients suffering from active, severe infections due to the increased risk of worsening of the patient's condition.

Severe immunocompromise

This medicine is not recommended for use in patients with severe immunocompromise since it may worsen the patient's condition.

Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

General warnings

Infusion related reactions

This medicine has been associated with severe infusion-related reactions, characterized by symptoms such as fever, chills, rigors, low blood pressure, hives, swelling, etc. The onset of these reactions usually ranges from 30 minutes to 2 hours after starting the first intravenous infusion. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.

Infections

This medicine should be used with caution due to the increased risk of severe and potentially life-threatening infections. Report any unusual symptoms such as a fever, diarrhea, sore throat, pain or burning during urination, etc. to the doctor immediately. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

Missed Dose

This medicine is usually given in multiple cycles. If you miss a scheduled appointment for receiving a dose of this medicine, call your doctor immediately for further instructions.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.

Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Interaction with Medicine

Live attenuated vaccines and related products

Adalimumab

Topotecan

Disease interactions

Autoimmune disorders

This medicine should be used with extreme caution in patients suffering from autoimmune disorders due to the increased risk of progressive multifocal leukoencephalopathy (PML) and death. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Cardiac Dysfunction

This medicine should be used with extreme caution in patients suffering from diseases of the heart due to the increased risk of worsening of the patient's condition. Close monitoring of heart function and vital signs is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Hepatitis B

This medicine should be used with extreme caution in patients with a history of Hepatitis B infection due to the increased risk of recurrent outbreaks and worsening of the patient's condition. Close monitoring of clinical condition, appropriate corrective measures, and replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Tumor Lysis Syndrome

This medicine should be used with extreme caution due to the increased risk of tumor lysis syndrome. This risk is especially higher in patients suffering from electrolyte abnormalities and kidney diseases. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition off the patient.

Bone marrow suppression

This medicine should be used with extreme caution in patients with a known history of bone marrow suppression since it may worsen the patient's condition. Close monitoring of complete blood cell counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Renal impairment

This medicine should be used with caution in patients with a history of kidney diseases due to the increased risk of serious adverse effects. Close monitoring of kidney function tests is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Food interactions

Information not available.

Lab interactions

Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
This medicine is usually administered by a qualified healthcare professional in the hospital or clinical setting. Inform the doctor if you have a known history of allergy to this medicine. Report to the doctor all your current medicines including any herbs and supplements as well as your medical conditions before receiving this medicine. Report any unusual and significant side effects to the doctor immediately.

Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works

This medicine prevents the growth and spread of cancer cells in the body.

Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antineoplastics, CD20 monoclonal antibodies, Antirheumatics

Schedule

Schedule H

[Internet]. Medicines.org.uk. 2018 [cited 27 July 2018]. Available from:

https://www.medicines.org.uk/emc/product/8878/smpc#STORAGE

[Internet]. 2018 [cited 27 July 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04141-3&d=201807271016933

[Internet]. Accessdata.fda.gov. 2018 [cited 27 July 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf

Related Questions

Question:
Sir my mother is a arthritis patient from past 10 years , the doctor who is treating my mother is su...more
Answer from Dr. Dewangan Sunil
Very good
Something doesn’t feel right?
Report an error

Information on this page was last updated on 28 Aug 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.